Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

December 9, 2019

Primary Completion Date

July 21, 2022

Study Completion Date

September 20, 2022

Conditions
Atopic Dermatitis
Interventions
DRUG

MEDI3506

multiple doses

DRUG

Placebo

multiple doses

Trial Locations (38)

3002

Research Site, East Melbourne

3053

Research Site, Carlton

3128

Research Site, Box Hill

6160

Research Site, Fremantle

10117

Research Site, Berlin

15831

Research Site, Mahlow

20246

Research Site, Hamburg

28100

Research Site, Alcobendas

28277

Research Site, Charlotte

28915

Research Site, Leganés

29303

Research Site, Spartanburg

32256

Research Site, Jacksonville

32806

Research Site, Orlando

33180

Research Site, Miami

35209

Research Site, Birmingham

38119

Research Site, Memphis

41003

Research Site, Seville

70808

Research Site, Baton Rouge

74136

Research Site, Tulsa

78213

Research Site, San Antonio

78229

Research Site, San Antonio

90404

Research Site, Santa Monica

02903

Research Site, Providence

01307

Research Site, Dresden

15-453

Research Site, Bialystok

25-355

Research Site, Kielce

90-436

Research Site, Lodz

60-681

Research Site, Poznan

96-100

Research Site, Skierniewice

50-566

Research Site, Wroclaw

NN18 9EZ

Research Site, Corby

HP11 2QW

Research Site, High Wycombe

CV8 1JD

Research Site, Kenilworth

HA6 2RN

Research Site, Northwood

RM1 3PJ

Research Site, Romford

BD18 3SA

Research Site, Shipley

DA14 6LT

Research Site, Sidcup

RG40 1XS

Research Site, Wokingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY